[Treatment of Parkinson's syndrome with L-dopa and its methylated derivatives: 3-OMD and 4-OMD associated with a decarboxylase inhibitor. Clinical and biochemical study].
D000368:Aged; D001545:Benserazide / Q000627:therapeutic use; D002262:Carboxy-Lyases / Q000037:antagonists & inhibitors*; D003863:Depression / Q000139:chemically induced; D004295:Dihydroxyphenylalanine / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use*; D008750:Methyldopa / Q000627:therapeutic use*; D008875:Middle Aged; D010243:Paralysis / Q000139:chemically induced; D010300:Parkinson Disease / Q000188:drug therapy*; D012893:Sleep Wake Disorders / Q000139:chemically induced; D013997:Time Factors
D006834:Hydrazines; D008750:Methyldopa; D004295:Dihydroxyphenylalanine; D001545:Benserazide; D002262:Carboxy-Lyases
Thérapeutique du syndrome de Parkinson par la L-dopa, ses dérivés méthylés 3-OMD et 4-OMD associés à un inhibiteur de la décarboxylase. Etude clinique et biochimique.